Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: Insights from the REACH registry

European Heart Journal

Volumn 29, Issue 24, 2008, Pages 3052-3060

  Mehta, Rajendra H ^a,b,l   Bhatt, Deepak L ^c   Steg, Ph Gabriel ^d   Goto, Shinya ^e   Hirsch, Alan T ^f   Liau, Chiau Suong ^g   Röther, Joachim ^h   Wilson, Peter W F ⁱ   Richard, Alain Jean ^j   Eagle, Kim A ^k   Ohman, E Magnus ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF MINNESOTA   (United States)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h KLINIKUM MINDEN   (Germany)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j SANOFI   (France)

^k UNIVERSITY OF MICHIGAN   (United States)

^l NONE

more..

Author keywords

Bypass; Coronary disease; Revascularization; Risk factors; Stroke

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROTHROMBOSIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DISEASE REGISTRY; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK MANAGEMENT; STROKE; THROMBOSIS;

AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; REGISTRIES; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WORLD HEALTH;

EID: 58049208306     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn478     Document Type: Article

References (21)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Texas: American Heart Association; 2005.
2. Seides SF, Borer JS, Kent KM, Rosing DR, McIntosh CL, Epstein SE. Long-term anatomic fate of coronary-artery bypass grafts and functional status of patients five years after operation. N Engl J Med 1978;298: 1213-1217.
3. Grondin CM, Campeau L, Lesperance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation 1984;70(Suppl. I):208-212.
4. de Feyter PJ, van Suylen RJ, de Jaegere PP, Topol EJ, Serruys PW. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993;21:1539-1549.
5. Weintraub WS, Jones EL, Craver JM, Guyton RA. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol 1994;73:103-112.
6. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S. Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: Results of the VA Cooperative Study. Circulation 1994;89:1138-1143.
7. Mangano DT, for the Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-1317.
8. Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987;94:773-783.
9. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
10. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO, for the CASS Investigators. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. J Am Coll Cardiol 1992;20:287-294.
11. Eagle KA, Guyton RA, Davidoff R, Edward FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology. http://www.acc.org/clinical/guidelines/cabg/cabg.pdf (9 June 2006).
12. De Backer GG. The new European guidelines on cardiovascular disease prevention - lifestyle, risk factors, and therapeutic goals. Presented at the ESC Congress 2003, Vienna, 30 August-3 September 2003. European Guidelines on Cardiovascular Disease Prevention. http://www.escardio.org/knowledge/guidelines/ (23 June 2007).
13. Foody JM, Ferdinand FD, Galusha D, Rathore SS, Masoudi FA, Havranek EP, Nilasena D, Radford MJ, Krumholz HM. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 2003;108(Suppl. I):24-28.
14. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151:786e1-710.
15. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW, for the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180- 189.
16. Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB Jr, Peterson ED, for the PREVENT IV Investigators. Outcomes associated with use of secondary prevention medications following coronary artery bypass graft surgery. Ann Thorac Surg 2007;83:993-1001.
17. Vanasse A, Courteau J, Niyonsenga T. Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care. BMC Cardiovasc Disord 2006;6:21.
18. Huang JV, Casebeer AW, Plomondon ME, Shroyer AL, McDonald GO, Fullerton D, Bell MR, Baltz J, Grover FL, Cunningham F. Prescription-filling rates for key medications in Veterans Affairs patients after coronary artery bypass grafting. Am J Health Syst Pharm 2004;61:1248-1252.
19. Mehta RH, Peterson ED, Califf RM. Performance measures have a major effect on cardiovascular outcomes: a review. Am J Med 2007;120:398-402.
20. Mehta RH, Montoye CK, Gallogly M, Baker P, Blount A, Faul J, Roychoudhury C, Borzak S, Fox S, Franklin M, Freundl M, Kline-Rogers E, LaLonde T, Orza M, Parrish R, Satwicz M, Smith MJ, Sobotka P, Winston S, Riba AA, Eagle KA, GAP Steering Committee of the American College of Cardiology. Improving quality in the care of acute myocardial infarction: The Guidelines Applied To Practice (GAP) Initiative in Southeast Michigan. JAMA 2002;287:1269-1276.
21. Reddy KS, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005;366:1744-1749.